Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance

Carol Durno, MD\textsuperscript{1,2}; Ayse Bahar Erkan, BSc\textsuperscript{3,4}; Vanessa Bianchi, PhD\textsuperscript{5}; Melissa Edwards, PhD\textsuperscript{1}; Melyssa Aronson, MSc\textsuperscript{2}; Melissa Galati, BSc\textsuperscript{1,4}; Eshetu G. Atenaifu, MSc\textsuperscript{2}; Gadi Abebe-Campino, MD\textsuperscript{4}; Aberer Al-Batashi, MD\textsuperscript{4}; Musa Alharbi, MD\textsuperscript{4}; Vahid Fallah Azad, MD\textsuperscript{4}; Hagit N. Baris, MD\textsuperscript{4}; Donald Basel, MD\textsuperscript{4}; Raymond Bedgood, MD\textsuperscript{4}; Anne Bendel, MD\textsuperscript{4}; Shay Ben-Shachar, MD\textsuperscript{4}; Deborah T. Blumenthal, MD\textsuperscript{4}; Maude Blundell, MSc\textsuperscript{4}; Miriam Bornhorst, MD\textsuperscript{4}; Annika Bronsme, MD\textsuperscript{4}; Elizabeth Cairney, MD\textsuperscript{5}; Sara Rhode, MSc\textsuperscript{4}; Shani Caspi, MD\textsuperscript{4}; Aghiad Chamdin, MD\textsuperscript{4}; Stefano Chiariavalli, MD\textsuperscript{4}; Shlomi Constantini, MD\textsuperscript{4}; Bruce Crooks, MD\textsuperscript{4}; Anirban Das, MD\textsuperscript{4}; Rina Dvir, MD\textsuperscript{4}; Roula Farah, MD\textsuperscript{4}; William D. Foulkes, MD\textsuperscript{4}; Zehavit Frenkel, MD\textsuperscript{4}; Bailey Gallinger, MSc\textsuperscript{4}; Sharon Gardner, MD\textsuperscript{4}; David Gass, MD\textsuperscript{4}; Mithra Ghalibafian, MD\textsuperscript{4}; Catherine Gilpin, MSc\textsuperscript{4}; Yael Goldberg, MD\textsuperscript{4}; Catherine Goudie, MD\textsuperscript{4}; Syed Ahmer Hamid, MD\textsuperscript{4}; Heather Hampel, MSc\textsuperscript{4}; Jordan R. Hansford, MD\textsuperscript{4}; Craig Harlos, MD\textsuperscript{4}; Nobuko Hijiyama, MD\textsuperscript{4}; Saunders Hsu, MD\textsuperscript{4}; Junne Kaminara, MD\textsuperscript{4}; Rejin Kebudi, MD\textsuperscript{4}; Jeffrey Knipstein, MD\textsuperscript{4}; Carl Koschmann, MD\textsuperscript{4}; Christian Kritz, MD\textsuperscript{4}; Valerie Larouche, MD\textsuperscript{4}; Alvaro Lassalette, MD\textsuperscript{4}; Scott Lindhorst, MD\textsuperscript{4}; Simon C. Ling, MD\textsuperscript{4}; Michael P. Link, MD\textsuperscript{4}; Rebecca Loret De Mola, MD\textsuperscript{4}; Rebecca Luiten, MSc\textsuperscript{4}; Michal Lurye, MD\textsuperscript{5}; Jamie L. Maciaszek, PhD\textsuperscript{4}; Vanan Magimairajantssai, MD\textsuperscript{5}; Ossama M. Maher, MD\textsuperscript{5}; Maura Massimino, MD\textsuperscript{5}; Rose B. McGee, MSc\textsuperscript{5}; Naureen Mushtaq, MD\textsuperscript{5}; Gary Mason, MD\textsuperscript{5}; Monica Newmark, MSc\textsuperscript{4}; Garth Nicholas, MD\textsuperscript{5}; Kim E. Nichols, MD\textsuperscript{5}; Theodore Nicolaides, MD\textsuperscript{5}; Enrico Opocher, MD\textsuperscript{6}; Michael Osborn, MD\textsuperscript{5}; Benjamin Oshrine, MD\textsuperscript{5}; Rachel Pearlman, MSc\textsuperscript{5}; Daniel Pettee, DO\textsuperscript{5}; Jan Rapp\textsuperscript{5}; Mohsin Rashid, MD\textsuperscript{5}; Alyssa Reddy, MD\textsuperscript{5}; Lara Reichman, MD\textsuperscript{5}; Marc Remke, MD\textsuperscript{5}; Gabriel Robbins, MD\textsuperscript{5}; Sumita Roy, MD\textsuperscript{5}; Magnus Sabel, MD\textsuperscript{5}; David Samuel, MD\textsuperscript{5}; Isabelle Scheers, MD\textsuperscript{5}; Kami Wolfe Schneider, MSc\textsuperscript{5}; Santanu Sen, MD\textsuperscript{5}; Duncan Stearns, MD\textsuperscript{5}; David Sumerauer, MD\textsuperscript{5}; Carol Swallow, MD\textsuperscript{5}; Leslie Taylor, RN, BSc\textsuperscript{5}; Gregory Thomas, MD\textsuperscript{5}; An Van Damme, MD\textsuperscript{5}; Ira Winer, MD\textsuperscript{5}; Michal Yalon, MD\textsuperscript{5}; Lee Yi Yen, MD\textsuperscript{5}; Michael Zapolotzek, MD\textsuperscript{5}; Shayna Zelcer, MD\textsuperscript{5}; David S. Ziegler, MD\textsuperscript{5}; Stefanie Zimmermann, MD\textsuperscript{5}; Cynthia Hawkins, MD\textsuperscript{5}; David Malkin, MD\textsuperscript{5}; Eric Bouffet, MD\textsuperscript{5}; Anita Villani, MD\textsuperscript{5}; and Uri Tabori, MD\textsuperscript{5}; On Behalf of the International Replication Repair Deficiency Consortium

PURPOSE Constitutional mismatch repair deficiency syndrome (CMMRD) is a lethal cancer predisposition syndrome characterized by early-onset synchronous and metachronous multiorgan tumors. We designed a surveillance protocol for early tumor detection in these individuals.

PATIENTS AND METHODS Data were collected from patients with confirmed CMMRD who were registered in the International Replication Repair Deficiency Consortium. Tumor spectrum, efficacy of the surveillance protocol, and malignant transformation of low-grade lesions were examined for the entire cohort. Survival outcomes were analyzed for patients followed prospectively from the time of surveillance implementation.

RESULTS A total of 193 malignant tumors in 110 patients were identified. Median age of first cancer diagnosis was 9.2 years (range: 1.7–39.5 years). For patients undergoing surveillance, all GI and other solid tumors, and 75% of brain cancers were detected asymptptomatically. By contrast, only 16% of hematologic malignancies were detected asymptomatically ($P < .001$). Eighty-nine patients were followed prospectively and used for survival analysis. Five-year overall survival (OS) was 90% (95% CI, 78.6 to 100) and 50% (95% CI, 39.2 to 63.7) when cancer was detected asymptptomatically and symptomatically, respectively ($P = .001$). Patient outcome measured by adherence to the surveillance protocol revealed 4-year OS of 79% (95% CI, 54.8 to 90.9) for patients undergoing full surveillance, 55% (95% CI, 28.5 to 74.5) for partial surveillance, and 15% (95% CI, 5.2 to 28.8) for those not under surveillance ($P < .0001$). Of the 64 low-grade tumors detected, the cumulative likelihood of transformation from low-to high-grade was 81% for GI cancers within 8 years and 100% for gliomas in 6 years.

CONCLUSION Surveillance and early cancer detection are associated with improved OS for individuals with CMMRD.

J Clin Oncol 39:2779-2790. © 2021 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION Constitutional mismatch repair deficiency (CMMRD) syndrome associated with inheritance of biallelic pathogenic variants in mismatch repair (MMR) genes (MLH1, PMS2, MSH2, and MSH6), leading to deficient
MMR during DNA replication.\(^2\) Loss of functional MMR results in a rapid accumulation of mutations and the development of cancers that are highly aggressive and display a hypermutant phenotype.\(^2,4\) Because of the nature of these tumors, commonly used chemotherapies and radiation are largely ineffective.\(^5\) Consequently, many patients with CMMRD develop symptomatic cancers and die regardless of treatment approach.\(^6,12\)

The most common tumors observed in these patients are early-onset CNS, GI, and hematologic malignancies with higher penetrance than other cancer predisposition syndromes.\(^13\) Although other cancer types have been reported in children and adults with CMMRD,\(^13,15,16\) the frequency and extent of these malignancies are not as well characterized. Surveillance protocols have previously been developed for several cancer predisposition syndromes such as hereditary breast-ovarian cancer and Li-Fraumeni syndromes and have significantly improved survival for screened patients.\(^17,20\) Effective surveillance relies on three central pillars.\(^21\) First, a surveillance protocol should include modalities that identify most cancer types presenting in at-risk individuals. Second, the recommended modalities should prove effective at early detection of asymptomatic tumors that can be resected or managed effectively with reduced treatment related morbidity. Third, a surveillance protocol must demonstrate that early asymptomatic tumor detection ultimately improves overall patient survival.

Initial efforts to establish surveillance for individuals with CMMRD began with anecdotal cases incorporating GI surveillance\(^22,23\) and serial brain magnetic resonance imaging (MRI), although surveillance approaches varied widely.\(^22,24,25\) Proposed surveillance guidelines for CMMRD were recently revised\(^26,27\) to include more comprehensive recommendations. However, current guidelines are based on expert opinion and no study has systematically evaluated the efficacy of surveillance and whether adherence affects overall survival (OS).

The International Replication Repair Deficiency Consortium (IRRDC) was formed in 2007 and currently includes pediatric and adult patients from more than 45 countries. Since 2008, surveillance recommendations were implemented as part of the management of these patients. Data from all registered IRRDC patients are collected prospectively from the time of enrollment.

The goal of this study was to systematically evaluate the proposed surveillance guidelines for CMMRD\(^27\) to determine whether current modalities are appropriate to detect the full spectrum of tumors seen and whether detecting asymptomatic tumors results in improved outcome.

**PATIENTS AND METHODS**

**Inclusion Criteria**

All patients were enrolled in the IRRDC with patient consent and institutional research ethics board approval (SickKids, Research Ethics Board no. 1000048813). Patients were diagnosed as having CMMRD through established genetic, clinical, and other molecular diagnostic criteria by the consortium genetic counselor (M.A.) based on criteria established by an international consensus.\(^13,28\) This group was termed full study cohort (Fig 1). Patients who did not completely fulfill these established criteria including suspected yet unconfirmed CMMRD were excluded. Since current evidence on CMMRD does not suggest an association between the cancer susceptibility of a patient and which of the four MMR genes is affected, we included all patients with CMMRD in this study and added the gene affected to our multivariable analysis.
repair deficiency syndrome as keywords and was restricted to English language publications. Malignant lesions and age of diagnosis were recorded. Authors were contacted to clarify patient identification to minimize duplication of cases.

Surveillance Data

The surveillance protocol used by the consortium was published in 2017 and includes the following: Brain MRI is to be implemented at diagnosis and repeated every 6 months. Whole-body MRI (WBMRI) should begin at age 6 years and is to be performed annually. Abdominal ultrasound and CBC should be performed at diagnosis and repeated every 6 months. Upper and lower endoscopy are recommended annually starting at 4-6 years of age. Further details of the protocol are outlined in the Data Supplement (online only). Data were obtained through ongoing follow-up for the full study cohort. In addition, a surveillance questionnaire was sent to each patient’s physician (Data Supplement). Medical documents, including pathology, surgical, endoscopy, and autopsy reports, were also reviewed. The end of patient follow-up date for the study was November 1, 2019.

To evaluate the efficacy of early cancer detection by the recommended guidelines, tumors from patients undergoing surveillance from the full study cohort were identified either as asymptomatic or symptomatic at diagnosis and the modalities that detected each tumor were reported. Data were also collected on all benign and low-grade lesions found in the full study cohort.

Prospective Cohort and Outcome Measures

To assess whether surveillance guidelines and early detection affect survival, we evaluated patients who were followed prospectively from 2008 (n = 89), the year surveillance was initiated (Fig 1). Patients in this prospective cohort were categorized as either full, partial, or no surveillance based on the level of surveillance they received. The full surveillance cohort (n = 33) comprised individuals who underwent routine screening using all the modalities recommended. The partial surveillance cohort (n = 20) included individuals who did not consistently undergo all screening modalities or from whom modalities were not performed at recommended intervals. Examples include individuals in whom only colonoscopy and CBC were performed, or for whom brain MRIs were performed at intervals > 6 months. The no surveillance cohort (n = 36) included individuals who did not receive any routine screening. Overall patient survival was determined for these three groups. Patients who were enrolled in the consortium
before 2008 (n = 21) and whose data were retrospectively collected were excluded from survival analysis. To test the role of early asymptomatic tumor detection and considering that patients with CMMRD develop synchronous and metachronous cancers, a secondary separate analysis of patient outcome was measured per tumor. Tumors were divided into two groups, symptomatic or asymptomatic, based on presentation at diagnosis. Tumor-specific survival was subsequently measured by comparing these two groups. To avoid further bias introduced by low-resource or high-resource based on the World Bank Global Index LMIC List 2020.

Statistical Analysis

For analysis of asymptomatic versus symptomatic tumor-specific survival, each tumor was treated as an independent entity and the unit of analysis was the tumor rather than the individual. Tumor-specific survival was defined as time to death or last follow-up from the diagnosis of brain, GI, or other tumors. For participants with multiple tumors, cause of death was attributed to one of the tumors and we censored tumors that were not the cause of death at the time of death. For patients, time to OS was defined in years from date of CMMRD diagnosis to the date of death or last follow-up.

Categorical variables such as sex, gene affected, and tumor types were summarized with counts and percentages. Continuous variables such as age at first cancer diagnosis and follow-up duration were summarized with median and range. One-way analysis of variance, Fisher’s exact test, and N–1 chi-squared test (for comparison of proportions) were used where appropriate for analysis of the prospective cohort demographics tables.

OS rates were calculated using the Kaplan-Meier product-limit method. Logrank test was used as a univariate analysis to assess potential prognostic factors. Cox proportional hazards model was also used to assess the joint effect of prognostic factors. All tests were two-tailed with a probability of < .05 considered statistically significance. Statistical analyses were performed using version 9.4 of the SAS System for Windows (Copyright 2002-2012 SAS Institute Inc, Cary, NC), and SPSS, Statistics for Windows, Version 22.0., IBM Corp (Armonk, NY).

RESULTS

Overall, 110 patients with confirmed CMMRD and 193 malignant tumors were identified (Fig 1). Two tumors were excluded from the remaining analysis as full information was not available. The full study cohort comprised 110 patients and 191 tumors that were used to determine the efficacy of the proposed surveillance modalities in malignant tumors and for analysis of low-grade lesions. Ongoing prospective data were collected for 89 patients. This established the prospective cohort for the survival analysis. Five patients did not develop cancer during the study with a median follow-up of 1.6 years (range, 0.68–4.98 years) and 84 developed 139 malignant tumors during the study time.

Tumor Spectrum for Patients With CMMRD

The spectrum of malignant tumors identified for IRRD patients (full study cohort) is presented in Figure 2A. Additional demographics are detailed in the Data Supplement. Overall, the median age of first cancer diagnosis was 9.2 years (range, 1.7-39.5 years). CNS tumors were the most common cancers observed (44%, n = 85; median age at diagnosis 9.9 years, range 2.3-38.5 years) followed by GI (27%, n = 52; median age at diagnosis 15.9 years, range 8.5-49.9 years) and hematologic malignancies (19%, n = 37; median age at diagnosis 10.5 years, range 2.2-29.9 years). We compared the prevalence of cancers in individuals with CMMRD from the literature (Data Supplement) to our cohort and revealed similar ratios. Ten percent of tumors (n = 19; median age at diagnosis 16.1 years, range 1.7-52.3 years) occurred in other organs, such as bone, soft tissue, genitourinary, and embryonal cancers.

In addition, adult type tumors, such as colorectal, breast, and genital tumors, were observed at young ages (31%, median age 17.9 years, range 8.5-52.3 years). Of the 52 patients who survived their initial cancers, 36 (69%) developed metachronous cancers (> 2 years between cancers). A detailed list of the malignant tumors identified for each IRRDC patient along with basic demographics is listed in the Data Supplement. Together, the high frequency of numerous cancers in multiple organ systems at a young age highlights the importance of implementing a multimodal surveillance protocol early in life.

Efficacy of Surveillance for Asymptomatic Tumor Detection

To test the efficacy of recommended modalities in detecting asymptomatic tumors, we looked specifically at individuals undergoing surveillance within the full study cohort (n = 56). We then analyzed the cancers developed during this period to determine which tumors were detected asymptotically or symptomatically (Fig 2B). Twenty CNS tumors were identified, including both malignant gliomas and embryonal tumors such as medulloblastoma. Both brain-specific and WBMRI were able to detect 15 (75%) asymptomatic CNS cancers. The five brain tumors that developed symptomatically while on surveillance were in patients who had intervals longer than six months between scans (n = 1, 1.5 years), or interruptions because of access or availability to surveillance modalities (n = 4). All 24 GI tumors were identified asymptotically by surveillance. Similarly, all five of the other solid tumors detected by surveillance were
asymptomatic. By contrast, only two of 12 (16%) hematopoietic malignancies were detected by current surveillance methods, both of which were identified incidentally.

**Survival Benefit for Asymptomatic Detection of Malignant Cancers**

Having established the tumor spectrum and potential benefit of the surveillance recommendations for patients with CMMRD, we examined the impact of early detection of asymptomatic malignant cancers on survival. Within the prospective cohort, 139 tumors were detected. Of those, 39 tumors (28%) were detected by surveillance tools before symptoms arose. All other tumors (72%, n = 100) were diagnosed after initial symptoms or signs. Survival analysis was performed per tumor. Five-year OS was 90% (95% CI, 78.6 to 100) and 50% (95% CI, 39.2 to 63.7) for

---

**FIG 2.** Tumor spectrum and efficacy of the surveillance modalities to detect asymptomatic malignant tumors in the full study cohort. (A) Distribution of malignant tumors from individuals with CMMRD. (B) Tumors detected during surveillance per tumor type. *P = .03 (brain) compared with literature cohort (brain) determined using “N–1” chi-squared test. ALL, acute lymphoblastic leukemia; AML, acute myelomonocytic leukemia; CMMRD, constitutional mismatch repair deficiency; IRRDC, International Replication Repair Deficiency Consortium.
asymptomatic versus symptomatic detection, respectively 
\( (P = .001, \text{ Fig 3A}) \). Having a large cohort in this study allowed for evaluation of the two most common cancer types. For CNS tumors (92% high-grade glioma, 6% medulloblastoma, and 2% CNS embryonal tumors), 5-year OS was 72% (95% CI, 49.5 to 100) for asymptomatic tumors (n = 15) and 33% (95% CI, 20.5 to 55.6) for symptomatic tumors (n = 53; \( P = .04, \text{ Fig 3B} \)). For GI cancers (n = 33, \text{ Fig 3C} ), OS was 100% (95% CI, 100 to 100) for tumors detected asymptomatically (n = 18) during surveillance compared with 81% (95% CI, 71.1 to 100) survival for symptomatic tumors (n = 15; \( P = .18 \)). Multivariable analysis for all tumors (Data Supplement) and for brain (Data Supplement) and colon (Data Supplement) separately confirmed the independent value of asymptomatic tumor detection in all cancers and brain tumors specifically.

**Survival Benefit for Patients With CMMRD Undergoing Surveillance**

We then tested the ability of the surveillance protocol to improve survival for patients with CMMRD. Patients in the prospective cohort (n = 89) were further divided into three groups: individuals undergoing full surveillance (n = 33), partial surveillance (n = 20), and no surveillance (n = 36; see Methods, Data Supplement). Patient demographics were similar between groups (Table 1). Only eight patients were older than 18 years when the surveillance was initiated.

Four-year OS was 79% (95% CI, 54.8 to 90.9) and 15% (95% CI, 5.2 to 28.8) for patients with CMMRD undergoing full surveillance versus those not undergoing surveillance \( (P < .0001, \text{ Fig 3D}) \). Patients undergoing partial
surveillance had favorable outcomes with 4-year OS of 54% (95% CI, 28.5 to 74.5; \( P < .001 \)).

To examine whether the observed differences in OS was a result of resource differences that affect availability or adherence to the surveillance protocol, we analyzed the distribution of patients from the full, partial, and no surveillance groups by country of origin (Table 1). The distribution of patients who did or did not undergo surveillance did not differ between high- and low-resource settings.

To address the lead time bias, the mortality ratio was calculated for the median follow-up of 25.4 months (Data Supplement). For the full surveillance cohort, mortality was 30% (10 of 33), which was significantly less \(( P = .001 \) than the nonsurveillance cohort at 72% (26 of 36). The partial surveillance cohort had a mortality of 40% (8 of 20) compared with the no surveillance cohort \(( P = .02 \). There was no significant difference in mortality between the full surveillance and partial surveillance cohorts. Eighty-nine patients from the prospective cohort were from 72 families. The penetrance of this syndrome and familial clustering did not affect presentation, tumor type, and outcome of patients in this study.

In multivariable analysis, including age, sex, gene affected, and resources available, surveillance was the single variable associated with improved OS in patients with CMMRD \(( P < .0001; \text{ Table 2} \).

### TABLE 1. Prospective Cohort Patient Demographics

| Demographic | F (n = 33) | P (n = 20) | N (n = 36) | \( P \) value |
|-------------|------------|------------|------------|---------------|
| Male:female | 13:20      | 11:9       | 15:21      | F \( \neq \) P: .39 |
| Median age (years) at last follow-up or death (range) | 13.9 (3.7-41.1) | 15.7 (5.3-44.7) | 13.5 (3.4-28.5) | F \( \neq \) P: .46 |
| Median age (years) at initiation of surveillance (range) | 9.9 (1.5-38.5) | 11.2 (3.0-39.5) | 11.0 (2.3-27.2) | F \( \neq \) P: .47 |
| Adults (18+ years) | 4 | 3 | 1 | F \( \neq \) P: .1 |
| Asymptomatic: symptomatic tumors | 23:28 | 15:20 | 1:52 | F \( \neq \) P: .001 |
| Patient location | | | | |
| High resource (n = 80) | 31 | 18 | 31 | F \( \neq \) P: .63 |
| Low resource (n = 9) | 2 | 2 | 5 | F \( \neq \) P: .3 |

*NOTE.\( P \) values were obtained using Fisher’s exact test or one-way analysis of variance where applicable.

Abbreviations: F, full surveillance; N, no surveillance; P, partial surveillance.

*Age at first cancer was used as a comparison.

### TABLE 2. Multivariable Overall Survival Analysis Using Cox Proportional Hazards Model for the Prospective Cohort

| Parameter | \( P \) * | Hazard Ratio | 95% CI Lower | 95% CI Upper |
|-----------|----------|--------------|--------------|--------------|
| Sex (F \( \neq \) M) | .7063 | 0.880 | 0.453 | 1.710 |
| Surveillance (no \( \neq \) full) | \(< .0001\) | 0.115 | 0.045 | 0.299 |
| Surveillance (no \( \neq \) partial) | .0012 | 0.262 | 0.116 | 0.589 |
| Gene affected (MLH1) | .4364 | 0.310 | 0.016 | 5.917 |
| Gene affected (MSH2) | .5634 | 0.504 | 0.049 | 5.154 |
| Gene affected (MSH6) | .4617 | 0.454 | 0.055 | 3.723 |
| Gene affected (PMS2) | .1944 | 0.251 | 0.031 | 2.024 |
| Resource setting (low \( \neq \) high) | .6628 | 1.254 | 0.453 | 3.475 |
| Age at diagnosis (continuous) | .3247 | 1.024 | 0.977 | 1.072 |

*P values were obtained from Wald-type chi-square test from Cox model.

Low-Grade CMMRD Tumors Transform to High-Grade Cancers

A total of 64 benign and low-grade lesions were detected in 54 patients (Fig 4A, Data Supplement). Polyposis and low-grade gliomas (LGG) were the most common tumors. To assess the risk of malignant transformation, we analyzed data for patients undergoing GI surveillance for at least 3 years (n = 19). Of these, 58% (n = 11) developed dysplastic polyps, all of which resulted in prophylactic colectomy (Fig 4B) by age 13.2 years (range, 9.2-25 years). Of the six nonresected LGG identified by surveillance, all revealed universal transformation to high-grade glioma at a median of 1.7 years (range, 1-5.7 years; Figs 4C and 4D). Cumulative likelihood of transformation over time revealed an 81% probability of colorectal polyps undergoing high-grade dysplastic changes within 8 years (Fig 4D). Similarly, for LGG, the likelihood of transformation into high-grade glioma was 100% in 6 years (Fig 4D).
DISCUSSION

This is the first prospective report on the impact of surveillance for individuals with CMMRD and demonstrates that a multimodal approach is associated with a survival benefit when these individuals adhere to the recommended surveillance guidelines. The large number of tumors that can develop in affected individuals during a short period enabled us to examine several important concepts associated with current surveillance recommendations.

With increased awareness and diagnosis of CMMRD, the tumor-risk spectrum of this syndrome is expanding (Fig 2A). This study confirms that CNS, GI, and hematologic cancers are the most common tumor types, but also highlights that a significant number of tumors in other tissues, including embryonal tumors such as Wilms tumor and neuroblastoma, are not uncommon during early childhood. In addition, malignancies such as breast cancer, sarcomas, and genitourinary tumors are observed particularly in patients beyond the pediatric years. Overall, the tumor spectrum for CMMRD, including 576 CMMRD-associated cancers (literature and consortium cohorts), supports the recommended screening modalities.

FIG 4. Low-grade tumors detected in patients with constitutional mismatch repair deficiency undergoing surveillance. (A) Distribution of low-grade tumors in the full study cohort (n = 64). (B) Percentage of polyps with high-grade dysplasia and the frequency of preventative surgery. (C) Magnetic resonance imaging scans showing tumor transformation and time to transformation of six nonresected low-grade gliomas. (D) Cumulative likelihood of high-grade transformation over time for brain (red) and GI (blue) tumors.
The benefit from early detection of asymptomatic cancers is thought to be related to complete surgical resection and possibly less aggressive adjuvant therapy. Although early detection of tumors has not shown to improve survival in other cancer syndromes and sporadic cancer types,29-31 our study reveals that early asymptomatic tumor detection is associated with a significant OS benefit, including in malignant gliomas where the role of gross total resection is still debated (Figs 3A-3C).

Another important observation in this study is that some patients with CMMRD have developed multiple metachronous cancers and as a result of prior therapies, exceeded the maximum tolerated lifetime dose limits for radiation and certain chemotherapy agents. Surveillance enables these patients to be managed with surgery and follow-up alone.

Lead time bias must be considered, as it may skew the observed survival benefit for the surveillance cohorts. To address this, we reported mortality ratios for the prospective cohort at the median follow-up (Data Supplement) and further demonstrated a significant increase in survival for the full surveillance cohort compared with the nonsurveillance cohort (P = .001). In addition, lead time bias is typically related to cancers where there is a long time between diagnosis and death. As the majority of CMMRD-associated cancers are rapidly lethal, this bias is less likely in this study.

The proposed modalities and screening frequency identified a large majority of asymptomatic brain tumors (75%), and all of the GI and other solid tumors in patients with CMMRD undergoing surveillance (Fig 2B). Perhaps, the most disappointing part of this study is the inability of current methods to reliably detect asymptomatic hematologic malignancies. Similar observations have been described in other leukemia-related cancer syndromes.32 Several options may be more successful including metabolic tests such as lactate dehydrogenase or the use of molecular assays such T-cell rearrangement in circulating tumor DNA. Strategies are needed as 43% of the deaths in patients undergoing surveillance were because of hematologic malignancies, whereas these cancers accounted for only 16% of the deaths in the nonsurveillance cohort (while brain tumors predominate 75%).

Low-grade malignancies are invariably detected in all surveillance protocols.17 Controversy exists regarding whether the transformation risk of these lesions is high enough to offer survival benefit.17,18,29 We observed a strikingly high rate of transformation into malignant and premalignant lesions for both LGG and colorectal polyps (Fig 4). This may be because of the extremely high rate of mutation accumulation especially with secondary mutations in POLE and TP53.3,33,34 Complete surgical resection of low-grade tumors, and total colectomy for patients with multiple high-grade dysplastic polyps may be lifesaving by preventing the development to higher-grade tumors.

Although aggressive, the benefit of the currently recommended surveillance protocol on OS of patients with CMMRD is striking (Fig 3D). This is justified as many patients develop multiple cancers in a synchronous or metachronous fashion resulting in extremely low long-term survival. The increased survival benefit associated with partial surveillance for patients with CMMRD is an intriguing finding. This may have management implications for patients with CMMRD worldwide where not all of the recommended modalities are readily available. Relatively simple but consistent follow-up with fewer modalities may still improve outcome for this devastating syndrome.35

Although surveillance recommendations were available to all patients with CMMRD since 2008, many centers decided not to burden their patients with such a cumbersome protocol because of the lack of robust evidence supporting the benefit of CMMRD surveillance recommendations. Other reasons for nonadherence to full and consistent surveillance may include poor access to care, lack of education, awareness, social and cultural norms, and physician opinions regarding the role of these protocols in cancer predisposition. However, a lack of awareness and resources on a systemic level does not appear to have influenced the results of this study (Table 1). As observed in other cancer syndromes,17,18 we hope this study provides strong evidence leading to a wider use and adherence to the current protocol.

There are several limitations to this study that should be discussed. First, as most patients with CMMRD do not reach adulthood, the spectrum of cancers that may present in adults is limited. As the cancer risks become more defined, modification of the protocol should be considered. Second, in our cohort, only one malignant tumor was identified with WBMRI. Nevertheless, the tumor spectrum observed in patients with CMMRD (Fig 2A) clearly demonstrates a need for extended modalities outside of CNS, GI, and hematologic screening. In Li-Fraumeni17,18 and hereditary pheochromocytoma or paraganglioma syndromes, WBMRI has been studied prospectively for efficacy and has been shown to play an important role in the detection of both benign and malignant lesions.37 Ultimately, a longer follow-up time and a larger cohort of long-term survivors would be required to determine efficacy of WBMRI for CMMRD. In addition, it is important to recognize that the level of surveillance adherence was the decision of the patient and clinician and may be based on various factors. Although we considered systemic differences (ie, resource setting) and found no correlation, future studies should investigate other potential factors that may be involved. Finally, it will be important to assess the psycho-social impact of living with this condition and following this aggressive surveillance protocol.

In summary, this study provides justification for the current protocol and demonstrates a significant survival benefit associated with undergoing surveillance in patients with CMMRD. Further work is required to enable better detection of some malignancies.
AFFILIATIONS

1Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON, Canada
2Mount Sinai Hospital, The Familial Gastrointestinal Cancer Registry at the Zane Cohen Centre for Digestive Disease, Toronto, ON, Canada
3The Hospital for Sick Children, The Arthur and Sonia Labatt Brain Tumour Research Centre, Toronto, ON, Canada
4University of Toronto, Institute of Medical Science, Toronto, ON, Canada
5Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
6Department of Pediatric Hematology-Oncology, Sheba Medical Center, Tel Hashomer, Israel
7Ministry of Health Oman, Child Health Specialist Muscat, Muscat, Oman
8Department of Pediatric Hematology Oncology, King Fahad Medical City, Riyadh, Saudi Arabia
9MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC), Tehran, Iran
10Rambam Health Care Campus, The Genetics Institute, Haifa, Israel
11Medical College of Wisconsin, Pediatrics, Milwaukee, WI
12Coliseum Medical Centers, Macon, GA
13Department of Pediatric Hematology-Oncology, Children’s Hospitals and Clinics of Minnesota, Minneapolis, MN
14Tel Aviv Sourasky Medical Center, Genetic Institute, Tel Aviv, Israel
15Oncology Division, Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
16Sutter Health, Cancer Risk Program, Sacramento, CA
17Children’s National Medical Center, Brain Tumor Institute, Washington, DC
18Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
19Department of Pediatrics, London Health Sciences Centre, London, ON, Canada
20Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH
21Sheba Medical Center, Cancer Research Center, Tel Hashomer, Israel
22Michigan State University, College of Human Medicine, Center for Bleeding and Clotting Disorders, East Lansing, MI
23Pediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
24Department of Pediatric Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
25Division of Hematology-Oncology, IWK Health Centre, Halifax, NS, Canada
26Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada
27Department of Pediatric Hemato-Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
28Lebanese American University Medical Center-Rizk, Beirut, Lebanon
29Departments of Oncology and Human Genetics, McGill University Health Centre, Cancer Genetics Program, Montreal, QC, Canada
30Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel
31Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON, Canada
32Department of Pediatric Hematology-Oncology, NYU Langone Health, New York, NY
33Department of Pediatric Hematology and Oncology, Atrium Health, Charlotte, NC
34Children’s Hospital of Eastern Ontario, Genetics, Ottawa, ON, Canada
35Department of Oncology, Hadassah Medical Center, Jerusalem, Israel
36Division of Oncology, McGill University Health Centre, Montreal, QC, Canada
37The Indus Hospital, Karachi, Sindh, Pakistan
38The Ohio State University Comprehensive Cancer Center, Internal Medicine, Columbus, OH
39The Royal Children’s Hospital Melbourne, Children’s Cancer Centre, Parkville, Victoria, Australia
40Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada
41Pediatric Hematology Oncology and Stem Cell Transplant, Columbia University Irving Medical Center, New York, NY
42Department of Pediatric Hematology-Oncology, Sutter Health, Sacramento, CA
43Dana-Farber Children’s Hospital Cancer Center, Pediatric Oncology, Boston, MA
44Department of Pediatric Hematology-Oncology, Istanbul University, Fatih, Istanbul, Turkey
45Department of Pediatric Neurology, Medical College of Wisconsin, Milwaukee, WI
46Department of Pediatric Hematology-Oncology, University of Michigan Medical School, Ann Arbor, MI
47Department of Pediatric Haematology and Oncology, Hospital of the Goethe University Frankfurt, Frankfurt am Main, Hessen, Germany
48Department of Hematology-Oncology, CHU de Quebec-Universite Laval, Quebec, QC, Canada
49Department of Pediatric Hematology-Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain
50Department of Hematology-Medical Oncology, Medical University of South Carolina, Charleston, SC
51Department of Pediatrics, Stanford Medicine, Stanford, CA
52Department of Pediatrics, Oregon Health & Science University, Portland, OR
53Department of Clinical Cancer Genetics, Banner MD Anderson Cancer Center, Gilbert, AZ
54Saint Jude Children’s Research Hospital, Memphis, TN
55Department of Pediatric Hematology-Oncology, CancerCare Manitoba, Winnipeg, MB, Canada
56Department of Pediatric Hematology-Oncology, Nicklaus Children’s Hospital, Miami, FL
57Aga Khan University Hospital, Karachi, Pakistan
58Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA
59Ann and Robert H Lurie Children’s Hospital of Chicago, Chicago, IL
60Division of Medical Oncology, University of Ottawa, Ottawa, ON, Canada
61Department of Oncology, Saint Jude Children’s Research Hospital, Memphis, TN
62Department of Pediatrics, University of Padua, Padova, Veneto, Italy
63Paediatric Haematology, Womens and Childrens Hospital (WCH), North Adelaide, South Australia, Australia
64Johns Hopkins All Children’s Hospital, Pediatric Hematology-Oncology, Saint Petersburg, FL
65Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
66Akrn Children’s Hospital, Akron, OH
67West Virginia University Cancer Institute, Morgantown, WV
68IWK Health Centre, Halifax, NS, Canada
69University of California San Francisco, San Francisco, CA
70McGill University Health Centre, Montreal, QC, Canada
71University Hospital Dusseldorf, Dusseldorf, Nordrhein-Westfalen, Germany
72Wayne State University, Detroit, MI
73Department of Pediatrics, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden
74Valleym Children’s Hospital, Madera, CA
75Univesite Catholique de Louvain La Faculte de Medecine, Bruxelles, Belgium
76Department of Pediatric Hematology-Oncology, Children’s Hospital Colorado, Aurora, CO
77Department of Pediatrics, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
78UH Rainbow Babies and Children’s Hospital Division of Pediatrics, Pediatric Neuro-oncology, Cleveland, OH
REFERENCES
1. McKusick VA, Kniffin CL: Mismatch Repair Cancer Syndrome. Baltimore, MD, John Hopkins University Press, 2015
2. Preston BD, Albertson TM, Herr AJ: DNA replication fidelity and cancer. Semin Cancer Biol 20:281-293, 2010
3. Shlien A, Campbell BB, de Borja R, et al: Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-mutated cancers. Nat Genet 47:257-262, 2015
4. Loeb LA: Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat Rev Cancer 11:450-457, 2011
5. Touat M, Li YY, Boynton AN, et al: Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580:517-523, 2020
6. Jincky J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7:335-346, 2006
7. Karran P, Attard N: Thiopurines in current medical practice: Molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8:24-36, 2008
8. Attarbaschi A, Carraro E, Abia O, et al: Non-Hodgkin lymphoma and pre-existing conditions: Spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica 101:1581, 2016
9. Fedir A, Fink D: Mutations in DNA mismatch repair genes: Implications for DNA damage signaling and drug sensitivity (review). Int J Oncol 24:1039-1047, 2004
10. Cahill DP, Levine KK, Betsensky RA, et al: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038, 2007

11. McFalone-Figueroa JL, Braun CJ, Stanciu M, et al: Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide. Cancer Res 75:3127, 2015

12. Hunter C, Smith R, Cahill DP, et al: A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987, 2006

13. Bakry D, Aronson M, Durno C, et al: Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the Constitutional Mismatch Repair Deficiency Consortium. Eur J Cancer 50:987-996, 2014

14. Wimmer K, Kratz CP: Constitutional mismatch repair-deficiency syndrome. Haematologica 95:699, 2010

15. Lavoine N, Colas C, Muleris M, et al: Constitutional mismatch repair deficiency syndrome: Clinical description in a French cohort. J Med Genet 52:770-778, 2015

16. Durno CA, Sherman PM, Aronson M, et al: Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMRD) syndrome. Eur J Cancer 51:977-983, 2015

17. Villani A, Shore A, Wasserman JD, et al: Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 17:1295-1305, 2016

18. Villani A, Tabori U, Schiffman J, et al: Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study. Lancet Oncol 12:559-567, 2011

19. de Jong AE, Hendriks YMC, Kleibeuker JH, et al: Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665-671, 2006

20. Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57: 75-89, 2007

21. Dobrow MJ, Hagens V, Chafe R, et al: Consolidated principles for screening based on a systematic review and consensus process. CMAJ 190:E422-E429, 2018

22. Durno CA, Aronson M, Tabori U, et al: Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 59:652-656, 2012

23. Sjursen W, Bjornevoll I, Engebretsen LF, et al: A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts. Fam Cancer 8:179-186, 2009

24. Aronson M, Gallinger S, Cohen Z, et al: Gastrointestinal findings in the largest series of patients with hereditary biallelic mismatch repair deficiency syndrome: Report from the International Consortium. Am J Gastroenterol 111:275-284, 2016

25. Vasen HFA, Ghorbanoghli Z, Bourdeaut F, et al: Guidelines for surveillance of individuals with constitutional mismatch repair deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J Med Genet 51:283, 2014

26. Durno C, Boland CR, Cohen S, et al: Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: A consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 152:1605-1614, 2017

27. Tabori U, Hansford JR, Achatz MI, et al: Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23:e32, 2017

28. Wimmer K, Kratz CP, Vasen HF, et al: Diagnostic criteria for constitutional mismatch repair deficiency syndrome: Suggestions of the European consortium “care for CMMRD” (C4CMMR-D). J Med Genet 51:355-365, 2014

29. Evans DG, Salvador H, Chang VY, et al: Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res 23:e46, 2017

30. Martin RM, Donovan JL, Turner EL, et al: Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP Randomized Clinical Trial. JAMA 319:923-933, 2018

31. Schilling FH, Spix C, Berthold F, et al: Neuroblastoma screening at one year of age. N Engl J Med 346:1047-1053, 2002

32. Porter CC, Druley TE, Erez A, et al: Recommendations for surveillance for children with leukemia-predisposing conditions. Clin Cancer Res 23:e14, 2017

33. Campbell BB, Light N, Fabrizio D, et al: Comprehensive analysis of hypermutation in human cancer. Cell 171:1042-1056.e10, 2017

34. Bouffet E, Larouche V, Campbell BB, et al: Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206-2211, 2016

35. Kebudi R, Arayit N, Abedalthagafi M, et al: Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings. Pediatr Blood Cancer 67:e28309, 2020

36. Jasperson KW, Kohlmann W, Gammon A, et al: Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer 13:257-265, 2014

37. Anupindi SA, Bedoya MA, Lindell RB, et al: Diagnostic performance of whole-body MRI as a tool for cancer screening in children with genetic cancer-predisposing conditions. Am J Roentgenol 205:400-408, 2015
Survival Benefit for Individuals With CMMRD

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.

For more information about ASCO’s conflict of interest policy, please refer to https://www.asco.org/wc/ascopubs/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Survival Benefit for Individuals With CMMRD Undergoing Surveillance

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc and ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Hagit N. Baris
Consulting or Advisory Role: Sanofi, Igcentify Ltd

Donna Basel
Consulting or Advisory Role: BioMarrin

Deborah T. Blumenthal
Consulting or Advisory Role: AstraZeneca, Novocure, Takeda

Miriam Bornhorst
Consulting or Advisory Role: AstraZeneca/MedImmune

Sara Rhode
Consulting or Advisory Role: Myriad Genetics

Travel, Accommodations, Expenses: Myriad Genetics

Roula Farah
Consulting or Advisory Role: Novo Nordisk

William D. Foulkes
Consulting or Advisory Role: Novo Nordisk

Research Funding: AstraZeneca

David Gass
Research Funding: X4 Pharmaceuticals

Heather Hampel
Stock and Other Ownership Interests: Genome Medical

Consulting or Advisory Role: InVitae, Genome Medical, Promega, 23andMe

Jordan R. Hansford
Consulting or Advisory Role: Bayer

Craig Harlos
Travel, Accommodations, Expenses: GlaxoSmithKline

Nobuko Hijja
Consulting or Advisory Role: Novartis, Incyte

Research Funding: Pfizer

Junne Kamihara
Stock and Other Ownership Interests: PanTher Therapeutics, ROME Therapeutics, TellBio

Consulting or Advisory Role: ROME Therapeutics, Third Rock Ventures, Foundation Medicine

Consulting or Advisory Role: PureTech, Ribon Therapeutics, ACD Biotechnne

Patents, Royalties, Other Intellectual Property: Patent on drug delivery device licensed to PanTher Therapeutics, Patents on Repeat RNA biomarkers and therapeutics licensed to Rome Therapeutics, Patents on Circulating Tumor Cell Biomarkers Licensed to TellBio Inc

Jeffrey Knipstein
Employment: PRA Health Sciences

Consulting or Advisory Role: Atheneum

Alvaro Lassaletta
Stock and Other Ownership Interests: Gilead Sciences

Consulting or Advisory Role: Shire, Jazz Pharmaceuticals, Roche, Servier

Travel, Accommodations, Expenses: Shire, Gilead Sciences

Simon C. Ling
Consulting or Advisory Role: Abbvie

Research Funding: Abbvie, Gilead Sciences

Michael P. Link
Consulting or Advisory Role: Incyte, ADC Therapeutics, Lilly, Steba Biotech, Mesoblast, GlaxoSmithKline, Syndax

Research Funding: Seattle Genetics, Janssen Oncology

Rebecca Loret de Mola
Employment: Huron Consulting

Maura Massimino
Consulting or Advisory Role: Oncoscience, Novartis

Gary Mason
Employment: Janssen Research & Development, Merck

Stock and Other Ownership Interests: Johnson & Johnson, Merck

Travel, Accommodations, Expenses: Janssen Research & Development

Kim E. Nichols
Stock and Other Ownership Interests: Incyte

Research Funding: Incyte/Novartis, Alpine Immune Sciences

Enrico Opocher
Consulting or Advisory Role: AstraZeneca

Travel, Accommodations, Expenses: AstraZeneca

Michael Osborn
Travel, Accommodations, Expenses: Amgen, Pfizer

Benjamin Oshrine
Stock and Other Ownership Interests: InCyte

Consulting or Advisory Role: Novartis, AstraZeneca

Kami Wolfe Schneider
Consulting or Advisory Role: Illumina

Marc Remke
Stock and Other Ownership Interests: Bayer, BB Biotech Ventures, BioNTech AG, InVitae, IDXX Laboratories

Lara Reichman
Consulting or Advisory Role: AstraZeneca

Open Payments Link: https://openpaymentsdata.cms.gov/physician/792397

Patrick Tomboc
Consulting or Advisory Role: UniCare Health Plan

Other Relationship: Journal of Genetic Counseling

Duncan Stearns
Consulting or Advisory Role: AstraZeneca

Ira Winer
Consulting or Advisory Role: Oncoceutics

David S. Ziegler
Consulting or Advisory Role: Bayer, Amgen

Research Funding: Johnson & Johnson

Travel, Accommodations, Expenses: Pfizer, Sobi, Shire, Roche

Cynthia Hawkins
Consulting or Advisory Role: Bayer

Patents, Royalties, Other Intellectual Property: IP for low-grade glioma and sarcoma fusion panels as well as medulloblastoma subgrouping panel

David Malkin
Consulting or Advisory Role: Bayer

Eric Bouffet
Consulting or Advisory Role: Novartis

Research Funding: Roche, Bristol Myers Squibb

No other potential conflicts of interest were reported.